Biography

Researcher at the Pharmacometrics research group of Uppsala University at the time of the Union Conference 2025. My PhD focus was on the application of pharmacometrics to improve the treatment of multi-drug resistant tuberculosis in children, specifically focusing on the pharmacokinetics of pediatric-friendly options of pretomanid, delamanid, moxifloxacin, and clofazimine, paediatric dosing evaluations, clinical trial designs.

Expertise

TB Diagnostics
Public Health

Key Impacts

QT interval prolongation in children taking moxifloxacin and clofazimine for rifampicin-resistant TB treatment in South Africa, India and the Philippines

Younger children had lower QTcF before and during RR-TB treatment. CFZ and metabolites of BDQ/DLM drove long-term QTcF prolongation, while MFX was the primary contributor at 2h post-dose.

Source: Conference 2024